1. Home
  2. CSGP vs UTHR Comparison

CSGP vs UTHR Comparison

Compare CSGP & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CoStar Group Inc.

CSGP

CoStar Group Inc.

HOLD

Current Price

$42.75

Market Cap

21.1B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$528.29

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSGP
UTHR
Founded
1987
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1B
23.9B
IPO Year
1998
1999

Fundamental Metrics

Financial Performance
Metric
CSGP
UTHR
Price
$42.75
$528.29
Analyst Decision
Buy
Buy
Analyst Count
13
14
Target Price
$74.77
$531.79
AVG Volume (30 Days)
5.2M
497.9K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.07
EPS
0.02
27.86
Revenue
$965,230,000.00
$1,483,300,000.00
Revenue This Year
$19.71
$7.05
Revenue Next Year
$12.40
$13.30
P/E Ratio
$2,141.50
$18.93
Revenue Growth
15.23
2.38
52 Week Low
$41.84
$266.98
52 Week High
$97.43
$548.12

Technical Indicators

Market Signals
Indicator
CSGP
UTHR
Relative Strength Index (RSI) 32.69 57.52
Support Level N/A $464.92
Resistance Level $49.03 $542.66
Average True Range (ATR) 1.58 14.24
MACD 0.12 1.62
Stochastic Oscillator 13.10 74.46

Price Performance

Historical Comparison
CSGP
UTHR

About CSGP CoStar Group Inc.

CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors spanning office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many well-respected brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence into Canada, the United Kingdom, Spain, and France.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: